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ABSTRACT
Many drugs are used in the treatment of multiple myeloma but thalidomide, lenalidomide, bortezomib, and dexamethasone and their combination 
remain the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical name is (3-methyl-1-(3-phenyl-2-pyrazin-2-
ylcarbonylamino-propanoyl) amino-butyl) boronic acid. Mechanisms by which it acts is usually by 26 SProteasome inhibition leading to degradation 
of anti-apoptotic proteins. Bortezomib is known to cause many side effects. Hence, we report a rare case of bortezomib-induced subconjunctival 
hemorrhage in our tertiary care hospital.
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INTRODUCTION
Multiple myeloma is a hematological malignancy of plasma cell 
origin. Many drugs are used in the treatment of multiple myeloma 
but thalidomide, lenalidomide, bortezomib, and dexamethasone and 
their combination remain the main stay of treatment. Time to disease 
progression was found superior with bortezomib when compared to 
other drugs. It is known to cause many adverse effects which include 
nausea, vomiting, constipation, insomnia, blurred vision, skin reactions, 
muscle, and joint pain [1]. Some of the ocular side effects include bilateral 
eye soreness, itching, redness, blepharitis, meibomitis, and multiple 
chalazion [2]. Hence, we report a rare case of bortezomib-induced 
subconjunctival hemorrhage in our tertiary care hospital.
CASE REPORT
Informed consent was obtained from the patient. A 55-year-old female, 
a known case of multiple myeloma post radiation therapy was started 
on chemotherapy with bortezomib, thalidomide, and dexamethasone 
combination on July 2015 and had completed six courses as on February 
2016. The patient was planned for bone marrow transplantation on 
mid February 2016. On the month of February patient walked in with 
complaints of severe redness and itching of right eye. Conjunctivitis 
was ruled out and ophthalmic examination showed patient vision to 
be normal and patient was diagnosed of subconjunctival hemorrhage 
(Fig. 1). Causes of subconjunctival hemorrhage were ruled out 
which includes local trauma, ocular inflammations, orbital injuries, 
conjunctival tumors, ocular amyloidosis, ocular adnexal tumors, 
and contact lens use. This led to the diagnosis of drug-induced 
subconjunctival hemorrhage. Bortezomib was suspected to be the 
causative agent and it was supported with the evidence of reduced 
platelet counts in biochemical assessment. Platelet counts became very 
low after six cycles of bortezomib and values are tabulated as follows 
(Table 1). All other lab parameters were normal, and patient was 
treated with hot water compress to treat subconjunctival hemorrhage. 
Subconjunctival hemorrhage resolved slowly and platelet counts also 
improved during the next follow-up visit.
DISCUSSION
Multiple myeloma is regarded as one of the most common hematological 
malignancy and is of plasma cell origin with an annual incidence 
of 4.3% per 100000 in the United States with age-adjusted to 2000 
population. It is more common in males and in blacks when compared 
to females and whites, respectively. Treatment of multiple myeloma has 
evolved over time starting from alkylator-based therapies to stem cell 
transplantation, bone marrow transplantation to use of novel anticancer 
drugs targeting tumorigenesis pathways with latest being monoclonal 
antibodies. First line drugs in both the induction as well maintenance 
regimens currently include thalidomide, lenalidomide, bortezomib, 
and dexamethasone used in different combinations [3]. The ubiquitin-
proteasome pathway plays a major role in various cellular events in the 
process of tumorigenesis in multiple myeloma.
Bortezomib (VALCADE at formerly PS 341) is a proteasome inhibitor 
approved by Food and Drug Administration in May 2003 [4] for 
treatment of newly diagnosed cases of multiple myeloma as well as 
relapse/refractory multiple myeloma. The molecular formula of 
bortezomib is C19H25BN4O4 and its chemical name is (3-methyl-1-
(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl) 
boronic acid. Mechanisms by which it acts is usually by 26S Proteasome 
inhibition leading to degradation of anti-apoptotic proteins. This 
further protects proapoptotic proteins from degradation resulting in 
programed cell death in malignant cells. It has been found that multiple 
myeloma cells show increased expression of nuclear factor-kappa B 
(NF-κB). Bortezomib inactivates NF-κB pathway. In multiple myeloma, 
there is a degradation of IκB due to phosphorylation by IKK which 
leads to translocation of NF-κB into the nucleus causing transcription 
of a series of pro-survival genes. Proteasome inhibition prevents the 
activation of NF-κB and hence forth increases the death of malignant 
cells. Major side effects include generalized weakness, gastrointestinal 
symptoms, low platelet counts, insomnia, bone and joint pain, and 
peripheral neuropathy [1]. Usually, anticancer drugs are known to 
cause many side effects but ocular side effects are very rare and in a 
study conducted recently with 130 patients in a tertiary care hospital 
only 10% had eye disorders when compared to another system 
examination [5]. Ocular side effects include blepharitis, conjunctivitis, 
chalazion, and severe uveitis [2]. In our case, patient after receiving 
six cycles of bortezomib-based chemotherapy developed severe 
thrombocytopenia which led to subconjunctival hemorrhage. All other 
causes were ruled out and causality assessment as per Naranjo’s scale 
was done, and a probable causal relationship was established [6]. 
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CONCLUSION
Multiple myeloma, one among the most common hematological 
malignancy and bortezomib being the first line drug of choice 
proper adverse drug monitoring is essential. Since a probable causal 
relationship is established in this case, further prospective studies can 
be undertaken to evaluate the incidence of ocular side effects associated 
with bortezomib.
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Fig. 1: Subconjunctival hemorrhage
Table 1: Platelet count before and after six cycles of bortezomib
Bortezomib cycle Platelet counts
Before first cycle 257×103/UL
After sixth cycle 73×103/UL
At last follow-up visit 208×103/UL
Table 2: Adverse drug reaction assessment
Naranjo’s scale Probable
Hartwig’s scale Mild severity
Thornton’s scale Not preventable
Adverse reaction was found to be mildly severe and not preventable 
as per Hartwig’s severity scale [7] and Thornton’s preventability 
scale [8], respectively (Table 2).
